Leslie Tubbs, Managing Director and Portfolio Manager at Zevenbergen Capital Investments, says Celgene Corporation (NASDAQ:CELG) has built a platform of innovation that started with the success of its product REVLIMID.
This company has been a leader in developing treatments for blood cancers. Celgene has had great success over the years with a product called REVLIMID, which is a treatment for multiple myeloma. The company saw growth from the initial product introduction, uptake by a growing number of patients and more recently from increased treatment duration driven by better patient outcomes.
They also have an active business development program which allows investment beyond their internal research, accessing new, innovative technologies in drug discovery. By doing so, Celgene is creating a platform of innovation where they can participate in the upside of these new technologies, without taking on all the downside risk in development of new drugs. This marriage of internal and external product development builds on the success of REVLIMID and expands opportunities in the coming years.
Celgene Corporation (CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane
April 29, 2013
Celgene Corporation (CELG) Grows Top Line and Expands Pipeline
September 09, 2015
Celgene Corporation (CELG) Looking at 20% Earnings Growth for 2016
February 03, 2016
The Internet Social Layer Builds Brands, Increases Ad Efficiency
December 08, 2010
Magellan Midstream Partners, L.P. (MMP) Builds and Repurposes Oil Infrastructure; 10% Annual Distribution Growth
March 25, 2013
